Fluorinated nitroimidazoles and their ruthenium complexes : potential hypoxia-imaging agents
With the goal of synthesizing nitroimidazole-based hypoxia imaging agents for the detection of cancerous tumours, the chemistry of halogen incorporation, especially fluorine, into the NI side-chain of nitroimidazoles was investigated. The coordination of these nitroimidazoles and other methyl (Me...
Main Author: | |
---|---|
Format: | Others |
Language: | English |
Published: |
2009
|
Online Access: | http://hdl.handle.net/2429/9944 |
id |
ndltd-UBC-oai-circle.library.ubc.ca-2429-9944 |
---|---|
record_format |
oai_dc |
collection |
NDLTD |
language |
English |
format |
Others
|
sources |
NDLTD |
description |
With the goal of synthesizing nitroimidazole-based hypoxia imaging agents for the
detection of cancerous tumours, the chemistry of halogen incorporation, especially
fluorine, into the NI side-chain of nitroimidazoles was investigated. The coordination of
these nitroimidazoles and other methyl (Me)-substituted imidazoles to Ru(II) and Ru(III)
centres was also investigated. The general objective was to combine the hypoxia-selective
nature of the nitroimidazole moiety and the DNA-binding properties of Ru to deliver the
active species selectively to its target.
The nitroimidazole compounds and Ru complexes were characterized in general by
a combination of NMR, IR and UV-Visible spectroscopies, as well as mass spectrometry,
cyclic voltammetry, conductivity and elemental analysis; six nitroimidazoles and eleven Ru
complexes were also characterized by X-ray crystallography.
The halogenated nitroimidazoles were synthesized using a standard amide coupling
reaction; this was used for the synthesis of EF5 [2-(2-nitro-l-H-imidazol-l-yl)-N-
(2,2,3,3,3-pentafluoropropyl) acetamide], a known, sensitive probe for quantifying the
amount of hypoxia within cells. Treatment of a desired acid with N-methylmorpholine and
zso-butylchloroformate, followed by addition of the appropriate amine (either
H₂NCH₂CX₃ or H₂NCH₂CX₂CX₃, where X= H, F, CI and/or Br) led to formation of the
halogenated nitroimidazole; 2-nitro- (2N₂), 2-methyl-5-nitro- (2Me₅N0₂) and 2-methyl-
4-nitro- (2Me₄N0₂) imidazole compounds were isolated in yields of 15 to 83 %.
The synthesis of EF5 (typical yield 45 %) was improved by coupling iodoacetic
acid with H₂NCH₂CF₂CF₃ to give ICH₂C(0)NHCH₂CF₂CF₃ (TF5) which was
subsequently reacted with 2N02Im and Cs₂C0₃ to yield the final product (78 %); this
2-step method circumvented the previously required 5-step synthesis. Other analogous
compounds were less stable than IF5, especially those species containing a C-Br moiety,
and they often decomposed in the presence of heat and/or light. Alteration of the
associated side-chain on EF5 by 'reversal' of its amide linkage was performed; however,
the biological activity of the derivative was significantly less than that of EF5.
A nitroimidazole (N0₂lm) containing side-chain with a highly reactive terminal
group, with the potential to exchange fluoride, was also sought. Attempts to isolate a
tosylated derivative of SR2508 [2-(2-mtro-l-H-irnidazol-l-yl)-N-(2-hydroxyethyl)
acetamide] proved to be futile. The reaction with tosyl chloride led to the formation of a
monochloro analogue of SR2508, presumably via the reactive tosylate intermediate, while
reaction with triflic anhydride led to an intramolecular cyclization of the side-chain to give
a compound whose X-ray structure was determined. The focus was then shifted to
F-for-Br exchange; however, attempts to perform such a task revealed that the C-N0₂
bond of the Im ring was more labile than the C-Br bond, and this resulted in the formation
of a 2-fluoroimidazole species. Further efforts to incorporate an F-atom into a
nitroimidazole side-chain were unsuccessful.
[Ru(II)(L)₆]²⁺ complexes were synthesized from [Ru(DMF)₆][CF₃S0₃]₃; DMF =
dimethylformamide, L = imidazole (Im), N-methylimidazole (NMelm) and 5-methylimidazole
(5MeIm). The 2-methylimidazole complex fram-[Ru(CO)(DMF)(2MeIm)₄]
[CF₃S0₃]₂ was synthesized via a reaction involving abstraction of CO from DMF; this
complex loses CO reversibly at ambient temperature to form [Ru(DMF)(2MeIm)₄]
[CF₃S0₃]₂ , and the DMF can be removed to generate [Ru(CF₃S0₃)x(2MeIm) ₄][CF₃S0₃]y
(x = 2, y = 0, or x = 1 = y). The X-ray structures of [Ru(Im)₆][CF₃S0₃]₂,
[Ru(NMeIm)₆][CF₃S0₃]₂ and [Ru(5MeIm)6][CF₃S0₃]₂ were obtained. Analogous
[Ru(II)(L)x] ₂+ nitroimidazole complexes (L = 2N0₂Im, x = 6; L = 4N0₂Im, x = 6; L =
2Me5N0₂Im, x = 5) were isolated from reaction with [Ru(DMF)6][CF₃S0₃]₃ . The
reaction with EF5 and SR2508 in EtOH yielded the bis-substituted complexes
[Ru(DMF)₂ (EF5)₂ (EtOH)₂][CF₃S0₃]₃ and [Ru(DMF)₄(SR2508)₂][CF₃SO₃]₃, respectively.
Ru(III) complexes of composition RuCl₃L₃ (L = 2N0₂Im, 4N0₂Im, 2Me₅N0₂Im,
metro) and RuCl₃L₂(EtOH) (L= EF5, SR2508) were synthesized directly from
RuCl₃»3H₂0. Their *H NMR spectra were typically broad and sometimes signals were not
observed; however, their paramagnetic, d5 low-spin composition was confirmed using the
Evans method.
Some new Ru(II) and Ru(III) bis-β -diketonate (acac = acetylacetonate; hfac =
1,1,1,5,5,5-hexafluoroacetylacetonate) Im and N0₂lm complexes were synthesized.
Reaction of two equiv. of an imidazole with c/s-[Ru(acac)₂ (MeCN)₂][CF₃S0₃]
(synthesized from Ru(acac) ₃ and CF₃S0₃H in MeCN) yielded Ru(III) complexes with
composition [Ru(acac)₂ (L) ₂][CF₃S0₃] (L = Im, NMelm, 2MeIm, 5MeIm, 2N0₂Im, metro,
EF5 and SR2508), the first four being structurally characterized by X-ray crystallography.
The analogous Ru(II) hfac complexes were isolated from a reaction of
cz'5-Ru(hfac) ₂(MeCN) ₂ (71) (synthesized from either Ru(hfac)₃ or Na[Ru(hfac)₃] and
CF₃S0₃H in MeCN) with two equiv. of imidazole to yield Ru(hfac)₂ (L)₂ (L = Im, NMelm,
2MeIm, 4(5)MeIm, 2N0₂Im, EF5 and SR2508). X-ray structures of 71 and Ru(hfac)₃
were obtained. Reaction of 71 with neat NMelm gave [Ru(hfac)CNMeIm)₄][hfac]. The
mixed ligand complex c/5-Ru(hfac)(acac)(MeCN)₂ (X-ray) was synthesized from the new
species Ru(hfac)₂ (acac), which was isolated from a reaction of 71 with Hacac.
In vitro assays for toxicity and monoclonal antibody (MoAb) binding with SCCVLT
cells were used to evaluate the potential of selected nitroimidazoles as hypoxia-selective
imaging agents. The toxicity, MoAb binding, cell accumulation and DNA-binding assays
were used to test the utility of selected Ru complexes for transporting and/or localizing
the coordinated nitroimidazoles within the cell. A preliminary radiosensitization study was
also performed with two Ru complexes.
In general, the nitroimidazoles (N0₂lms) and Ru complexes were non-toxic under
both oxic and hypoxic conditions. The accumulation of the N0₂lms within the cell
required hypoxic conditions, while the amount of N0₂ lm bound within the hypoxic cells
correlated with its one-electron reduction potential, the N0₂lms with the more positive
reduction potentials giving the higher concentrations. The interaction of the fluorescently
labeled MoAbs (ELK3-51 and ELK5-A8) with the N0₂lms depended on the length, size
and composition of the halogenated side-chains. The Ru-N0₂lm complexes displayed
relatively high cell accumulation and DNA-binding levels when compared to literature data
for other Ru complexes. The most interesting result came from the MoAb assay in which
the cells treated with [Ru(acac)₂ (EF5)₂] [CF₃S0₃] afforded a fluorescence signal four
times greater than that seen for EF5 itself. === Science, Faculty of === Chemistry, Department of === Graduate |
author |
Baird, Ian Robert |
spellingShingle |
Baird, Ian Robert Fluorinated nitroimidazoles and their ruthenium complexes : potential hypoxia-imaging agents |
author_facet |
Baird, Ian Robert |
author_sort |
Baird, Ian Robert |
title |
Fluorinated nitroimidazoles and their ruthenium complexes : potential hypoxia-imaging agents |
title_short |
Fluorinated nitroimidazoles and their ruthenium complexes : potential hypoxia-imaging agents |
title_full |
Fluorinated nitroimidazoles and their ruthenium complexes : potential hypoxia-imaging agents |
title_fullStr |
Fluorinated nitroimidazoles and their ruthenium complexes : potential hypoxia-imaging agents |
title_full_unstemmed |
Fluorinated nitroimidazoles and their ruthenium complexes : potential hypoxia-imaging agents |
title_sort |
fluorinated nitroimidazoles and their ruthenium complexes : potential hypoxia-imaging agents |
publishDate |
2009 |
url |
http://hdl.handle.net/2429/9944 |
work_keys_str_mv |
AT bairdianrobert fluorinatednitroimidazolesandtheirrutheniumcomplexespotentialhypoxiaimagingagents |
_version_ |
1718588419573022720 |
spelling |
ndltd-UBC-oai-circle.library.ubc.ca-2429-99442018-01-05T17:35:01Z Fluorinated nitroimidazoles and their ruthenium complexes : potential hypoxia-imaging agents Baird, Ian Robert With the goal of synthesizing nitroimidazole-based hypoxia imaging agents for the detection of cancerous tumours, the chemistry of halogen incorporation, especially fluorine, into the NI side-chain of nitroimidazoles was investigated. The coordination of these nitroimidazoles and other methyl (Me)-substituted imidazoles to Ru(II) and Ru(III) centres was also investigated. The general objective was to combine the hypoxia-selective nature of the nitroimidazole moiety and the DNA-binding properties of Ru to deliver the active species selectively to its target. The nitroimidazole compounds and Ru complexes were characterized in general by a combination of NMR, IR and UV-Visible spectroscopies, as well as mass spectrometry, cyclic voltammetry, conductivity and elemental analysis; six nitroimidazoles and eleven Ru complexes were also characterized by X-ray crystallography. The halogenated nitroimidazoles were synthesized using a standard amide coupling reaction; this was used for the synthesis of EF5 [2-(2-nitro-l-H-imidazol-l-yl)-N- (2,2,3,3,3-pentafluoropropyl) acetamide], a known, sensitive probe for quantifying the amount of hypoxia within cells. Treatment of a desired acid with N-methylmorpholine and zso-butylchloroformate, followed by addition of the appropriate amine (either H₂NCH₂CX₃ or H₂NCH₂CX₂CX₃, where X= H, F, CI and/or Br) led to formation of the halogenated nitroimidazole; 2-nitro- (2N₂), 2-methyl-5-nitro- (2Me₅N0₂) and 2-methyl- 4-nitro- (2Me₄N0₂) imidazole compounds were isolated in yields of 15 to 83 %. The synthesis of EF5 (typical yield 45 %) was improved by coupling iodoacetic acid with H₂NCH₂CF₂CF₃ to give ICH₂C(0)NHCH₂CF₂CF₃ (TF5) which was subsequently reacted with 2N02Im and Cs₂C0₃ to yield the final product (78 %); this 2-step method circumvented the previously required 5-step synthesis. Other analogous compounds were less stable than IF5, especially those species containing a C-Br moiety, and they often decomposed in the presence of heat and/or light. Alteration of the associated side-chain on EF5 by 'reversal' of its amide linkage was performed; however, the biological activity of the derivative was significantly less than that of EF5. A nitroimidazole (N0₂lm) containing side-chain with a highly reactive terminal group, with the potential to exchange fluoride, was also sought. Attempts to isolate a tosylated derivative of SR2508 [2-(2-mtro-l-H-irnidazol-l-yl)-N-(2-hydroxyethyl) acetamide] proved to be futile. The reaction with tosyl chloride led to the formation of a monochloro analogue of SR2508, presumably via the reactive tosylate intermediate, while reaction with triflic anhydride led to an intramolecular cyclization of the side-chain to give a compound whose X-ray structure was determined. The focus was then shifted to F-for-Br exchange; however, attempts to perform such a task revealed that the C-N0₂ bond of the Im ring was more labile than the C-Br bond, and this resulted in the formation of a 2-fluoroimidazole species. Further efforts to incorporate an F-atom into a nitroimidazole side-chain were unsuccessful. [Ru(II)(L)₆]²⁺ complexes were synthesized from [Ru(DMF)₆][CF₃S0₃]₃; DMF = dimethylformamide, L = imidazole (Im), N-methylimidazole (NMelm) and 5-methylimidazole (5MeIm). The 2-methylimidazole complex fram-[Ru(CO)(DMF)(2MeIm)₄] [CF₃S0₃]₂ was synthesized via a reaction involving abstraction of CO from DMF; this complex loses CO reversibly at ambient temperature to form [Ru(DMF)(2MeIm)₄] [CF₃S0₃]₂ , and the DMF can be removed to generate [Ru(CF₃S0₃)x(2MeIm) ₄][CF₃S0₃]y (x = 2, y = 0, or x = 1 = y). The X-ray structures of [Ru(Im)₆][CF₃S0₃]₂, [Ru(NMeIm)₆][CF₃S0₃]₂ and [Ru(5MeIm)6][CF₃S0₃]₂ were obtained. Analogous [Ru(II)(L)x] ₂+ nitroimidazole complexes (L = 2N0₂Im, x = 6; L = 4N0₂Im, x = 6; L = 2Me5N0₂Im, x = 5) were isolated from reaction with [Ru(DMF)6][CF₃S0₃]₃ . The reaction with EF5 and SR2508 in EtOH yielded the bis-substituted complexes [Ru(DMF)₂ (EF5)₂ (EtOH)₂][CF₃S0₃]₃ and [Ru(DMF)₄(SR2508)₂][CF₃SO₃]₃, respectively. Ru(III) complexes of composition RuCl₃L₃ (L = 2N0₂Im, 4N0₂Im, 2Me₅N0₂Im, metro) and RuCl₃L₂(EtOH) (L= EF5, SR2508) were synthesized directly from RuCl₃»3H₂0. Their *H NMR spectra were typically broad and sometimes signals were not observed; however, their paramagnetic, d5 low-spin composition was confirmed using the Evans method. Some new Ru(II) and Ru(III) bis-β -diketonate (acac = acetylacetonate; hfac = 1,1,1,5,5,5-hexafluoroacetylacetonate) Im and N0₂lm complexes were synthesized. Reaction of two equiv. of an imidazole with c/s-[Ru(acac)₂ (MeCN)₂][CF₃S0₃] (synthesized from Ru(acac) ₃ and CF₃S0₃H in MeCN) yielded Ru(III) complexes with composition [Ru(acac)₂ (L) ₂][CF₃S0₃] (L = Im, NMelm, 2MeIm, 5MeIm, 2N0₂Im, metro, EF5 and SR2508), the first four being structurally characterized by X-ray crystallography. The analogous Ru(II) hfac complexes were isolated from a reaction of cz'5-Ru(hfac) ₂(MeCN) ₂ (71) (synthesized from either Ru(hfac)₃ or Na[Ru(hfac)₃] and CF₃S0₃H in MeCN) with two equiv. of imidazole to yield Ru(hfac)₂ (L)₂ (L = Im, NMelm, 2MeIm, 4(5)MeIm, 2N0₂Im, EF5 and SR2508). X-ray structures of 71 and Ru(hfac)₃ were obtained. Reaction of 71 with neat NMelm gave [Ru(hfac)CNMeIm)₄][hfac]. The mixed ligand complex c/5-Ru(hfac)(acac)(MeCN)₂ (X-ray) was synthesized from the new species Ru(hfac)₂ (acac), which was isolated from a reaction of 71 with Hacac. In vitro assays for toxicity and monoclonal antibody (MoAb) binding with SCCVLT cells were used to evaluate the potential of selected nitroimidazoles as hypoxia-selective imaging agents. The toxicity, MoAb binding, cell accumulation and DNA-binding assays were used to test the utility of selected Ru complexes for transporting and/or localizing the coordinated nitroimidazoles within the cell. A preliminary radiosensitization study was also performed with two Ru complexes. In general, the nitroimidazoles (N0₂lms) and Ru complexes were non-toxic under both oxic and hypoxic conditions. The accumulation of the N0₂lms within the cell required hypoxic conditions, while the amount of N0₂ lm bound within the hypoxic cells correlated with its one-electron reduction potential, the N0₂lms with the more positive reduction potentials giving the higher concentrations. The interaction of the fluorescently labeled MoAbs (ELK3-51 and ELK5-A8) with the N0₂lms depended on the length, size and composition of the halogenated side-chains. The Ru-N0₂lm complexes displayed relatively high cell accumulation and DNA-binding levels when compared to literature data for other Ru complexes. The most interesting result came from the MoAb assay in which the cells treated with [Ru(acac)₂ (EF5)₂] [CF₃S0₃] afforded a fluorescence signal four times greater than that seen for EF5 itself. Science, Faculty of Chemistry, Department of Graduate 2009-07-02T19:31:13Z 2009-07-02T19:31:13Z 1999 1999-11 Text Thesis/Dissertation http://hdl.handle.net/2429/9944 eng For non-commercial purposes only, such as research, private study and education. Additional conditions apply, see Terms of Use https://open.library.ubc.ca/terms_of_use. 17639646 bytes application/pdf |